13F HOLDINGS REPORT
Versant Venture Management, LLC
Quarter ended Q2 2024 · Filed August 7, 2024 · Accession 0000950123-24-007328
Total Value
$77.3M
Positions
8
Other Managers
0
Confidential Omitted
No
Holdings (8)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | CRISPR Therapeutics AG | CRSP | 498,558 | $26.9M | 34.84% |
| 2 | Contineum Therapeutics, Inc. | CTNM | 918,163 | $16.2M | 20.92% |
| 3 | Skye Bioscience, Inc. | SKYE | 2,007,704 | $16.1M | 20.81% |
| 4 | Repare Therapeutics, Inc. | 760273102 | 2,646,657 | $8.7M | 11.30% |
| 5 | Adverum Biotechnologies, Inc. | 00773U108 | 506,821 | $3.5M | 4.50% |
| 6 | Passage Bio, Inc. | PASG | 4,026,417 | $3.2M | 4.14% |
| 7 | Gritstone Oncology, Inc. | 39868T105 | 3,561,150 | $2.2M | 2.85% |
| 8 | Aligos Therapeutics, Inc. | ALGS | 1,457,937 | $510,278 | 0.66% |